Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- ATTOGENE CORPORATION
- Proposal award date
- 2023-09-01
- Contract end date
- 2024-08-31
- UEI
- M5VSPH6FK6D6
- Solicitation number
- PA22-176
- Topic code
- 400
Research abstract
Summary/AbstractThe past decade has brought an escalating growth of important new commercial applications for RNA.
RNA molecules have emerged as the preeminent regulators of gene expression. They have a unique ability to
edit genomes and destabilize gene products. New diagnostic applications for RNA are continually being
discovered. Last but not least, modified mRNA nanoparticle formulations are enabling the development of new
vaccines and cellular therapies with a speed and efficacy unrivaled by other processes. This newfound
success has driven increased interest and efforts in many areas of RNA research. Researchers are constantly
discovering important new roles for RNA in the regulation of cellular processes. It has also opened the door to
many new commercial opportunities for startups and large pharmaceutical and diagnostic companies alike.
Accordingly, massive effort is now directed to production scale-up and large-scale manufacturing of RNA
molecules. As production increases, there is a far greater need for care and control of manufacturing
processes. This is especially true for RNA since it is quite vulnerable to degradation by contaminating enzymes
in the surrounding environment.As production scales and costs increase, more attention must be paid to strict process control and
quality management. For example, manufacturing of RNA for regulated therapeutic and diagnostic applications
must be performed in a certified RNAse-free environment. Current commercial methods to verify the absence
of RNAse require expensive equipment and hours to perform. The cost and time required to perform RNAse
testing hinders the productivity of manufacturers and researchers alike. A new rapid tool to test for unwanted
RNA contamination would great assist researchers and manufacturers who must frequently test their
environments and supply chain materials.In Phase I, we will create a novel prototype lateral flow test for the sensitive detection of RNAse. Our
work will produce a test kit product with several important advantages over currently available tools:
Convenience: Our test will be portable and not require bulky, expensive lab equipment. Sensitivity: Our test will
be at least 5-times more sensitive than current methods. Time: Users will see their results in less than 15
minutes rather than hours. These combined advantages of our proposed product will create a highly effective
tool to further support the continuing innovation in RNA therapeutics and research.
Specific Aim #1: Optimize the incubation buffer and RNA oligonucleotide sequence to improve RNAse assay
sensitivity.
Specific Aim #2: Produce a more sensitive fluorescent version of the lateral flow RNAse detection assay.
Specific Aim #3: Enable testing of solid surfaces using swab wipes.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
Research funding history
7 SBIR/STTR records share this UEI (2019–2025). Reported award amounts total $1,565,137. Reported amounts are not federal obligations.
Phases: Phase I
Agencies: Department of Health and Human Services, National Science Foundation, Department of Commerce
Agency intelligence
Department of Health and Human Services
Back to SBIR/STTR Research Awards